Strategy

New mediums of technology must be utilized correctly to reap full benefits.

Brexit and the pandemic continue to complicate flow of international talent.

New regulations set stage for updated ESG considerations.

Why purpose-driven firms are now more important than ever.

Cross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.

What’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.

Explicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.

Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.

It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.

Mazur talks about his commitment to drug development and what it takes to succeed in the industry today.

Mary Jo Struttmann, executive director of alliance management for Astellas discusses how to form strategic partnerships to bring new drugs to market and how to navigate partnerships, alliance dynamics, and potential challenges in 2022 and beyond.

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Assessing the road ahead for Chinese biotech.

Licensing deals, strategy, and COVID among factors to consider for companies entering Chinese pharma M&A.

Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.

With a strong pharma background that includes bringing non-US biotechs stateside in the rare diseases space, Rami Levin, CEO of Saniona, talks about the importance of growing his company’s business and his dedication to that mission.

Biopharma must step up amidst growing oncology market.

Pharma moves beyond promoting products to increase recognition of company names.

Pandemic lockdowns push pharma into brand-new era of social engagement.

How pharmaceutical leaders at established companies can still disrupt the status quo and change the game.

Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.

Using the interview process to ensure high organizational standards.

With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.

Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.